Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06597058 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

A Phase 2 study of Alzheimer Disease, sponsored by Noah Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
103
Enrollment target
16
Study locations

NCT06597058: Active Phase 2 study of Alzheimer Disease, sponsored by Noah Pharmaceuticals.

NCT06597058 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Noah Pharmaceuticals. The registered enrollment target is 103 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06597058, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Noah Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
103 participants
Enrollment target
16
Study locations

Study Summary

This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 months from Screening of the first patient until the last follow-up of the last patients.

Primary Outcome

CDR - Global Score: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The CDR scale is a widely used dementia staging instrument that produces a global score. This study will use global score for estimation, comparisons and analysis. The global score ranges from 0 to 3. The sites are instructed to use a standardized online calculator for scoring. This resulting

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG MAR

Study Locations (16)

Florida

  • Accel Research Sites (Noah Clinical Site 019) - DeLand
  • Health Awareness (Noah Clinical Site 020) - Jupiter
  • Life Well Research Center (Noah Clinical Site 008) - Miami
  • Regenerate Primary Medical Research (Noah Clinical Site 003) - Miami
  • Miami Jewish Health (Noah Clinical Site 023) - Miami
  • Neurology Associates of Ormond Beach (Noah Clinical Site 015) - Ormond Beach
  • International Medical Investigational Centers (Noah Clinical Site 001) - Palmetto Bay
  • Best Choice Medical and Research Service (Noah Clinical Site 025) - Pembroke Pines
  • Denali Health Plant City, LLC (Noah Clinical Site 024) - Plant City

Arizona

  • Scottsdale Clinical Trials (Noah Clinical Site 017) - Scottsdale

California

  • Marvel Clinical Research (Noah Clinical Site 010) - Huntington Beach

Massachusetts

  • Boston Clinical Trials (Noah Clinical Site 006) - Boston

New Mexico

  • IMA Clinical Research (Noah Clinical Site 004) - Albuquerque

North Carolina

  • Carolina Research Center, Inc. (Noah Clinical Site 009) - Shelby

Oklahoma

  • Tekton Research (Noah Clinical Site 002) - Yukon

Texas

  • Olympus Clinical Research (Noah Clinical Site 014) - Katy

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2024-10-16
Est. Completion 2026-02-15
Phase Phase 2
Noah Pharmaceuticals

1 total trials

What the registry record for NCT06597058 still lists

NCT06597058 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which MAR is the first listed.

NCT06597058 lists 16 locations in 8 states (Florida, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT06597058 about?

NCT06597058 is a clinical study titled "Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill". This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very mild to severe Alzhei...

What is the current status of trial NCT06597058?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2024-10-16. Estimated completion is 2026-02-15.

What conditions does trial NCT06597058 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT06597058?

The interventions under investigation include: MAR (DRUG).

Who is sponsoring clinical trial NCT06597058?

This trial is sponsored by Noah Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06597058 being conducted?

This trial has 16 study locations across Arizona, California, Florida, Massachusetts, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06597058's enrollment target sits among peer trials

103 150th of 306 higher than 157 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06597058, the US trial registry maintained by the National Library of Medicine. NCT06597058 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.